RxDoctor Payments DataLook up a doctor →

John Leung, MD

Gastroenterology · Boston, MANPI 1447328711

Payments from drug & device makers

$2,820,746in general payments, 2019–2025

Across 1,596 payments — averaging $1767.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$671K
  • AstraZeneca$586K
  • Sanofi$257K
  • Regeneron Healthcare Solutions, Inc.$219K
  • Takeda Pharmaceuticals U.S.A., Inc.$215K
  • Bristol Myers Squibb$147K
  • plus $725K from 49 others
$11,794in research payments, 2019–2025

Across 14 payments — averaging $842.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$10K
  • AbbVie$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,820,746 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$50,416
Medicare patients
136
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →